BR0009448A - Métodos de tratamento de um câncer recidivo em um mamìfero, de tratamento de um linfoma não-de-hodgkin em um paciente, de tratamento de um câncer transformado em um mamìfero e de tratamento de uma neoplasia em um mamìfero, kit para uso no tratamento de uma neoplasia em um mamìfero, e, uso de vincristina lipossÈmica - Google Patents

Métodos de tratamento de um câncer recidivo em um mamìfero, de tratamento de um linfoma não-de-hodgkin em um paciente, de tratamento de um câncer transformado em um mamìfero e de tratamento de uma neoplasia em um mamìfero, kit para uso no tratamento de uma neoplasia em um mamìfero, e, uso de vincristina lipossÈmica

Info

Publication number
BR0009448A
BR0009448A BR0009448-0A BR0009448A BR0009448A BR 0009448 A BR0009448 A BR 0009448A BR 0009448 A BR0009448 A BR 0009448A BR 0009448 A BR0009448 A BR 0009448A
Authority
BR
Brazil
Prior art keywords
mammal
treating
neoplasm
cancer
lymphoma
Prior art date
Application number
BR0009448-0A
Other languages
English (en)
Other versions
BRPI0009448B1 (pt
BRPI0009448B8 (pt
Inventor
Andreas H Sarris
Fernando Cabanillas
Patricia M Logan
Clive T R Burge
James H Goldie
Murray S Webb
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of BR0009448A publication Critical patent/BR0009448A/pt
Publication of BRPI0009448B1 publication Critical patent/BRPI0009448B1/pt
Publication of BRPI0009448B8 publication Critical patent/BRPI0009448B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE UM CâNCER RECIDIVO EM UM MAMìFERO, DE TRATAMENTO DE UM LINFOMA NãO-DE-HODGKIN EM UM PACIENTE, DE TRATAMENTO DE UM CâNCER TRANSFORMADO EM UM MAMìFERO E DE TRATAMENTO DE UMA NEOPLASIA EM UM MAMìFERO, KIT PARA USO NO TRATAMENTO DE UMA NEOPLASIA EM UM MAMìFERO, E, USO DE VINCRISTINA LIPOSSÈMICA". Esta invenção proporciona métodos para tratar neoplasias em um mamífero. Em particular, a invenção proporciona métodos para tratar de varios tipos de linfomas, incluindo as formas recidivas de linfoma não-de-Hodgkin. Estes métodos envolvem a administração de alcalóides da pervinca encapsulados por lipossoma, por exemplo a vincristina, a um mamífero com um linfoma.
BRPI0009448A 1999-04-01 2000-03-31 kit para uso no tratamento de uma neoplasia em um mamífero BRPI0009448B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (3)

Publication Number Publication Date
BR0009448A true BR0009448A (pt) 2002-01-08
BRPI0009448B1 BRPI0009448B1 (pt) 2018-09-11
BRPI0009448B8 BRPI0009448B8 (pt) 2021-05-25

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009448A BRPI0009448B8 (pt) 1999-04-01 2000-03-31 kit para uso no tratamento de uma neoplasia em um mamífero

Country Status (14)

Country Link
EP (3) EP2266537B1 (pt)
JP (3) JP2002541088A (pt)
AT (1) ATE442839T1 (pt)
AU (1) AU777572B2 (pt)
BR (1) BRPI0009448B8 (pt)
CA (1) CA2366787C (pt)
CY (1) CY1109641T1 (pt)
DE (1) DE60042968D1 (pt)
DK (2) DK2266537T3 (pt)
ES (2) ES2524141T3 (pt)
HK (1) HK1152246A1 (pt)
IL (4) IL145720A0 (pt)
PT (1) PT1169021E (pt)
WO (1) WO2000059473A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
JP2002541088A (ja) * 1999-04-01 2002-12-03 イネックス ファーマシューティカルズ コーポレイション リンパ腫の治療のための組成物および方法
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2002312777B2 (en) * 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
ES2521672T3 (es) * 2002-05-17 2014-11-13 Celgene Corporation Formulaciones farmacéuticas para el tratamiento del cáncer
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
BRPI0513007A (pt) * 2004-07-09 2008-04-22 Schering Ag terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
CA2736564A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
SI2254571T1 (sl) 2008-03-18 2015-10-30 Genentech, Inc. Kombinacije konjugata protitelo proti HER2-zdravilo in kemoterapevtskih sredstev ter postopki uporabe
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
JP6419710B2 (ja) 2012-11-20 2018-11-07 スペクトラム ファーマシューティカルズ 治療的使用のためのリポソーム封入ビンクリスチンの調製のための改良法
US20140205543A1 (en) * 2013-01-24 2014-07-24 Memorial Sloan-Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
JP2002541088A (ja) * 1999-04-01 2002-12-03 イネックス ファーマシューティカルズ コーポレイション リンパ腫の治療のための組成物および方法

Also Published As

Publication number Publication date
AU4060600A (en) 2000-10-23
CY1109641T1 (el) 2014-08-13
PT1169021E (pt) 2009-11-18
AU777572B2 (en) 2004-10-21
IL212389A (en) 2015-07-30
ATE442839T1 (de) 2009-10-15
EP2266537B1 (en) 2014-09-03
JP2012158602A (ja) 2012-08-23
BRPI0009448B1 (pt) 2018-09-11
EP2266537A2 (en) 2010-12-29
EP2266537A3 (en) 2012-02-22
HK1152246A1 (en) 2012-02-24
EP1169021A1 (en) 2002-01-09
IL212390A (en) 2014-08-31
DE60042968D1 (de) 2009-10-29
EP1985285A2 (en) 2008-10-29
IL212389A0 (en) 2011-06-30
IL145720A0 (en) 2002-07-25
EP1169021B1 (en) 2009-09-16
DK1169021T3 (da) 2010-01-11
JP5981214B2 (ja) 2016-08-31
WO2000059473A1 (en) 2000-10-12
CA2366787A1 (en) 2000-10-12
ES2524141T3 (es) 2014-12-04
DK2266537T3 (en) 2014-12-15
JP2002541088A (ja) 2002-12-03
EP1985285A3 (en) 2009-08-12
JP2015071631A (ja) 2015-04-16
IL212390A0 (en) 2011-06-30
CA2366787C (en) 2013-03-12
ES2333400T3 (es) 2010-02-22
IL145720A (en) 2011-05-31
BRPI0009448B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BR0009448A (pt) Métodos de tratamento de um câncer recidivo em um mamìfero, de tratamento de um linfoma não-de-hodgkin em um paciente, de tratamento de um câncer transformado em um mamìfero e de tratamento de uma neoplasia em um mamìfero, kit para uso no tratamento de uma neoplasia em um mamìfero, e, uso de vincristina lipossÈmica
LV11430A (lv) 2-Piridilmetilenpoliazamakrociklofosfonskabes to kompleksi un atvasinajumi izmantosanai par kontrastvielam
TR200402579T4 (tr) Kristalin monohidrat, bunun imalat yöntemi ve bir ilaç maddesinin imalatında kullanımı
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
ATE67679T1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
BR9908273A (pt) Formulações
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0115323A (pt) Uso de cci-779 como agente antineoplástico
AU5624699A (en) Use of 5ht-6 antagonists
BR0009480A (pt) Soluções de poliuretano com unidades de estrutura de alcoxissilano
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DE69835824D1 (de) Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
TR199701121T1 (xx) Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
SE0100684D0 (sv) New subject-matter
ES2191206T3 (es) Nueva utilizacion de la creatina.
FI933506A (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaatteja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
ZA981558B (en) Inclusion complexes in aqueous solution
IL127930A0 (en) Verapamil as a medicament for the treatment of angina
ATE464063T1 (de) Topisch applizierbare kosmetische oder pharmazeutische zusammensetzung zur prävention oder behandlung androgener alopezie
TR200002707T2 (tr) Yeni bileşikler
RU2002111815A (ru) Способ лечения хронической гонореи

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: INEX PHARMACEUTICALS CORPORATION (CA), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US)

B25A Requested transfer of rights approved

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (

Free format text: TRANSFERIDO DE: INEX PHARMACEUTICALS CORPORATION

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 31/03/2020

B15V Prolongation of time limit allowed